PMID- 7925148
OWN - NLM
STAT- MEDLINE
DCOM- 19941121
LR  - 20190813
IS  - 0013-9580 (Print)
IS  - 0013-9580 (Linking)
VI  - 35
IP  - 5
DP  - 1994 Sep-Oct
TI  - Efficacy and tolerance of long-term, high-dose gabapentin: additional 
      observations.
PG  - 1032-7
AB  - Gabapentin (GBP) has shown antiepileptic efficacy and good tolerance in clinical 
      trials. Much remains to be learned about its clinical use. As a participating 
      center in the US Gabapentin Study Group, we report observations that have 
      practical implications for patient management. Twenty-three patients with 
      intractable partial-onset seizures initiated open-label treatment after a blinded 
      placebo-controlled add-on dose efficacy study. In the titration phase, GBP and 
      concurrent antiepileptic drugs (AEDs) were adjusted to achieve optimal efficacy 
      on maximally tolerated GBP doses. Nine patients had no significant improvement in 
      seizure control and discontinued GBP. The remaining 14 patients were observed 
      while treated long-term with stable-dose GBP and concurrent AEDs. Improvement was 
      maintained as long as patients were followed: < or = 4 years. The 
      protocol-allowed upper dose limit, 2,400 mg/day, was well tolerated by 16 of 23 
      patients, indicating that higher doses may be tolerated. GBP discontinuation did 
      not cause rebound increases in seizure frequency. The most common adverse events 
      (AEs) (in 14 of 23) were similar to those induced by concurrent AEDs and 
      responded to reduction of concurrent AEDs. Many patients reported positive 
      psychostimulatory effects. These observations extend previous findings indicating 
      that GBP is an effective and well-tolerated drug for treatment of partial-onset 
      seizures.
FAU - Handforth, A
AU  - Handforth A
AD  - Neurology Service, Department of Veterans Affairs Medical Center, West Los 
      Angeles, California 90073.
FAU - Treiman, D M
AU  - Treiman DM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Epilepsia
JT  - Epilepsia
JID - 2983306R
RN  - 0 (Acetates)
RN  - 0 (Amines)
RN  - 0 (Anticonvulsants)
RN  - 0 (Cyclohexanecarboxylic Acids)
RN  - 0 (Placebos)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
RN  - 6CW7F3G59X (Gabapentin)
SB  - IM
MH  - Acetates/administration & dosage/adverse effects/*therapeutic use
MH  - Adult
MH  - *Amines
MH  - Anticonvulsants/administration & dosage/adverse effects/*therapeutic use
MH  - *Cyclohexanecarboxylic Acids
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Drug Tolerance
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Gabapentin
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Dropouts
MH  - Placebos
MH  - *gamma-Aminobutyric Acid
EDAT- 1994/09/01 00:00
MHDA- 1994/09/01 00:01
CRDT- 1994/09/01 00:00
PHST- 1994/09/01 00:00 [pubmed]
PHST- 1994/09/01 00:01 [medline]
PHST- 1994/09/01 00:00 [entrez]
AID - 10.1111/j.1528-1157.1994.tb02551.x [doi]
PST - ppublish
SO  - Epilepsia. 1994 Sep-Oct;35(5):1032-7. doi: 10.1111/j.1528-1157.1994.tb02551.x.